What is Vinta Bio?
Vinta Bio is a Philadelphia-based entity specializing in comprehensive process development, Good Manufacturing Practice (GMP) manufacturing, and stringent quality control services tailored for the complex needs of cell and gene therapies. The company's expertise is crucial for advancing these cutting-edge therapeutic modalities from the laboratory to clinical application and commercialization.
How much funding has Vinta Bio raised?
Vinta Bio has raised a total of $64M across 1 funding round:
Other Financing Round
$64M
Other Financing Round (2023): $64M with participation from Decheng Capital
Key Investors in Vinta Bio
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies. With over $2.1 billion in capital, the firm aims to build legendary companies by leveraging revolutionary technologies and strong market presence.
What's next for Vinta Bio?
The recent major strategic investment into Vinta Bio signals a pivotal moment for the company, likely enabling accelerated expansion of its service offerings, enhancement of its manufacturing capabilities, and broader market penetration. This capital infusion is expected to fuel further innovation and solidify Vinta Bio's position as a key partner in the cell and gene therapy ecosystem, supporting the scaling of critical manufacturing infrastructure.
See full Vinta Bio company page
